Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Four serum tumor markers (CEA, SCC, NSE, ProGRP) were examined simultaneously.
|
31424643 |
2020 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thirty-eight patients (35%) had tumors with high PGRN expression, and there was a trend of elevated pre-operative CEA and CA19-9 levels in patients with high PGRN-expressing tumors compared to those with low PGRN-expressing tumors (CEA, 49% vs. 21%; CA19-9, 21% vs. 7%).
|
30378010 |
2020 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
After treatment, clinical efficacy, tumor markers levels (CEA and CYFRA21-1), serum vascular endothelial growth factor (VEGF) levels and adverse reactions were compared between two groups.
|
30570865 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, the tumor markers for breast cancer (CA 15-3 and CEA) were analyzed in both groups.
|
31412345 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlation of Prox1 immunohistochemical expression with tumor size, proliferative index (Ki67), and calcitonin and CEA serum levels prior to surgery was tested for significant correlations.
|
31001799 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The serum tumor markers CEA, CA125 and CA153 in a 240 mg/kg/d SPG-56 decreased by 54.8%, 91.8%, and 90.3%, respectively.
|
30651572 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased primary tumor and hilar lymph node SUVmax, solid nodule, centrally located tumor and increased CEA level predicted the increased risk of mediastinal lymph node metastasis.
|
31127706 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On evaluation, laboratory findings detected the negative serum tumor markers CEA, CA 125, CA 15-3 and CA 19-9.
|
31805975 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutant allele frequencies in plasma were significantly associated with metastasis (liver, P = 0.00004, lymph node, P = 0.008, number of metastatic organs, P = 0.0006), tumor markers (CEA, P = 0.000007, CA19-9, P = 0.006, LDH, P = 0.00001), and tumor diameter (maximum, P = 0.00002, sum of diameter, P = 0.00009).
|
30575318 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On multivariable logistic analysis, patients with higher neutrophil-lymphocyte ratio (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.09-1.19), higher CEA levels (OR, 1.25; 95% CI, 1.04-1.50), larger tumors (OR, 1.10; 95% CI, 1.04-1.15) and suspicious lymph nodes (OR, 2.05; 95% CI, 1.25-3.36) were more likely to have preoperative and postoperative score discordance.
|
31410852 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lack of immunohistochemical expression of TRIM72 in the tumor was significantly and independently associated to recurrence.A recent report by Chen et al. has shown that TRIM72 can be measured in plasma for colon carcinoma detection as an alternative to CEA or CA19.9, with lower levels in patients with carcinoma.
|
30852740 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor marker CEA is a known member of the IgG supergene family.
|
31088643 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariable analysis indicated both the CEA and tumor location were independent predictors of LRFS.
|
30651116 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Preoperative CEA levels were associated with age, BMI, ASA and tumour stage.
|
30822523 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, RDW-CV was significantly positively correlated with abnormal high values of tumor serum markers CEA and CA19-9 (P < 0.05).
|
30854125 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest cells (and tumors) have different levels of susceptibility for tPDT even though they all express CEA.
|
31828541 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We established that response rate and PFS in regorafenib treatment are independent of tumor localization, Ras status or biomarkers such as CEA and CA 19-9.
|
29940763 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The treatment efficacy, levels of sPD-L1 tumor marker CEA (carcino-embryonic antigen), and T-lymphocyte subsets (CD4+, CD3+, CD8+, CD29+) were compared between the two groups.
|
31128008 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A-kinase-interacting protein 1 expression was elevated in tumor tissue compared with paired adjacent tissue (P < .001), and high AKIP1 tumor tissue expression was correlated with poor pathological differentiation (P < .001), tumor size >5 cm (P = .001), lymph node metastasis (P = .016), higher TNM stages (P < .001), and abnormal CEA level (>5 ng/mL) (P = .035).
|
31782840 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All achieved excellent tumor response on CT scans with marked falls in tumor markers CA19-9 and CEA as well as ≥1 year of progression-free survival.
|
31102323 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There were differences neither between both groups considering the capacity of PET/CT to detect regional (p = 0.261) and distant involvement (p = 0.876), nor regarding the levels of tumor markers (p = 0.160 for CA19-9; p = 0.708 for CEA).
|
30022384 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The number of subjects with abnormal values of tumor marker CEA has decreased from 56.8% (enrollment visit) to 50% in the sixth visit (p<0.01).
|
29135093 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The scoring system predicting pleural invasion could be defined as follows: pl risk score = 3 (tumor diameter in CT ≥ 24 mm) + 3 (tumor contact length with pleura in CT ≥ 16 mm) + 3 (smoking index ≥ 400) + 3 (clinically lymph node positive) + 2 (tumor with cavity in CT) + 2 (serum CEA level > 4.4 ng/mL).
|
30888590 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analyses indicated that a high expression of hnRNP AB was significantly associated with preoperative carcinoembryonic antigen (CEA; P<0.001) and carbohydrate antigen 19-9 (P=0.014) levels, tumour size (P=0.022) and infiltration (P=0.026), lymph node metastasis (P<0.001) and Tumour-Node-Metastasis stage (P<0.001).
|
31819776 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report the radiolabeling, pharmacokinetic evaluation, and determination of tumor targeting capacity of the previously validated anti-CEA MFE23-scFv-based N-terminal trimerbody (MFE23<sup>N</sup>-trimerbody), and the results are compared to those obtained for the monomeric MFE23-scFv.
|
30726099 |
2019 |